IL124850A0 - Inhibitors of interleukin-1beta converting enzyme and processes for their production - Google Patents
Inhibitors of interleukin-1beta converting enzyme and processes for their productionInfo
- Publication number
- IL124850A0 IL124850A0 IL12485096A IL12485096A IL124850A0 IL 124850 A0 IL124850 A0 IL 124850A0 IL 12485096 A IL12485096 A IL 12485096A IL 12485096 A IL12485096 A IL 12485096A IL 124850 A0 IL124850 A0 IL 124850A0
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- inhibitors
- processes
- production
- converting enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Crystallography & Structural Chemistry (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14513296A IL145132A0 (en) | 1995-12-20 | 1996-12-20 | N-acyl amio derivatives, pharmaceutical compositions containing the same and processes for their production |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/575,641 US6008217A (en) | 1995-12-20 | 1995-12-20 | Inhibitors of interleukin-1β converting enzyme |
US08/598,332 US5874424A (en) | 1995-12-20 | 1996-02-08 | Inhibitors of interleukin-1β converting enzyme |
US08/712,878 US5985863A (en) | 1996-09-12 | 1996-09-12 | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
US3149596P | 1996-11-26 | 1996-11-26 | |
US08/761,483 US6204261B1 (en) | 1995-12-20 | 1996-12-06 | Inhibitors of interleukin-1β Converting enzyme inhibitors |
PCT/US1996/020843 WO1997022619A2 (en) | 1995-12-20 | 1996-12-20 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
Publications (1)
Publication Number | Publication Date |
---|---|
IL124850A0 true IL124850A0 (en) | 1999-01-26 |
Family
ID=27534345
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12485096A IL124850A0 (en) | 1995-12-20 | 1996-12-20 | Inhibitors of interleukin-1beta converting enzyme and processes for their production |
IL124850A IL124850A (en) | 1995-12-20 | 1998-06-11 | Elevated Trotocellular Compounds in Interleukin-Converting Enzyme Inhibitors - Pharmaceutical Preparations Containing Them and Processes for Their Preparation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL124850A IL124850A (en) | 1995-12-20 | 1998-06-11 | Elevated Trotocellular Compounds in Interleukin-Converting Enzyme Inhibitors - Pharmaceutical Preparations Containing Them and Processes for Their Preparation |
Country Status (24)
Country | Link |
---|---|
US (7) | US6204261B1 (sh) |
EP (3) | EP2295442A3 (sh) |
JP (3) | JP4205762B2 (sh) |
KR (1) | KR100561504B1 (sh) |
CN (1) | CN1229412A (sh) |
AP (4) | AP2002002540A0 (sh) |
AU (1) | AU735075B2 (sh) |
BG (2) | BG108927A (sh) |
BR (2) | BR9612258B1 (sh) |
CA (1) | CA2239904C (sh) |
CZ (2) | CZ300171B6 (sh) |
GE (1) | GEP20022638B (sh) |
HK (1) | HK1089435A1 (sh) |
IL (2) | IL124850A0 (sh) |
IN (1) | IN182290B (sh) |
IS (1) | IS4771A (sh) |
MX (1) | MX9805016A (sh) |
NO (1) | NO326882B1 (sh) |
NZ (2) | NZ326610A (sh) |
PL (1) | PL190736B1 (sh) |
SK (1) | SK287195B6 (sh) |
TR (3) | TR200201216T2 (sh) |
UA (1) | UA66337C2 (sh) |
WO (1) | WO1997022619A2 (sh) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6531467B2 (en) | 1996-09-12 | 2003-03-11 | Idun Pharmaceuticals, Inc. | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6610683B2 (en) | 1996-09-12 | 2003-08-26 | Idun Pharmaceuticals, Inc. | Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
US6200969B1 (en) | 1996-09-12 | 2001-03-13 | Idun Pharmaceuticals, Inc. | Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
DK0946502T3 (da) | 1996-10-11 | 2003-04-07 | Abbott Gmbh & Co Kg | Sulfonamidinhibitorer for det interleukin-1beta-omdannende enzym |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
KR20000049050A (ko) * | 1996-10-11 | 2000-07-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 술폰아미드 치환된 아스파르트산 인터루킨-1β 전환 효소 억제제 |
EP1466921A1 (en) * | 1996-12-06 | 2004-10-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1 beta converting enzyme |
DE69736984T2 (de) * | 1996-12-06 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des interleukin-1-beta konvertierenden enzyms |
FR2766188B1 (fr) * | 1997-07-15 | 2000-02-11 | Hoechst Marion Roussel Inc | Nouveau procede de preparation de derives amines d'alkyloxy furanone, composes issus de ce procede et utilisation de ces composes |
WO1999046248A1 (en) | 1998-03-09 | 1999-09-16 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
PT1064298E (pt) | 1998-03-19 | 2009-01-02 | Vertex Pharma | Inibidores de caspasas |
FR2777279B1 (fr) * | 1998-04-08 | 2004-08-13 | Hoechst Marion Roussel Inc | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
FR2777889B1 (fr) * | 1998-04-27 | 2004-07-09 | Hoechst Marion Roussel Inc | Nouveaux derives de l'acide octahydro-6,10-dioxo-6h- pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de composes therapeutiquement actifs |
FR2777888B1 (fr) * | 1998-04-27 | 2004-07-16 | Hoechst Marion Roussel Inc | Nouveaux derives de l'acide (3,4,7,8,9,10-hexahydro-6,10- dioxo-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxylique, leur procede de preparation et leur application a la preparation de medicaments |
US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6544951B2 (en) | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6703500B2 (en) * | 1998-08-19 | 2004-03-09 | Vertex Pharmaceuticals, Incorporated | Method of preparing bicyclic intermediates from piperazic acid or an ester thereof useful in the manufacture of caspase inhibitors |
US6559304B1 (en) * | 1998-08-19 | 2003-05-06 | Vertex Pharmaceuticals Incorporated | Method for synthesizing caspase inhibitors |
US6177565B1 (en) | 1998-08-19 | 2001-01-23 | Vertex Pharmaceuticals Inc. | Process for synthesizing piperazic acid |
US6201118B1 (en) | 1998-08-19 | 2001-03-13 | Vertex Pharmaceuticals Inc. | Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor |
JP2002538151A (ja) | 1999-03-02 | 2002-11-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンの可逆的インヒビターとして有用な化合物 |
TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
FR2802927B1 (fr) * | 1999-12-28 | 2002-03-01 | Hoechst Marion Roussel Inc | Nouveaux derives de diazepine carboxamide, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et leur nouvelle utilisation |
US6515173B1 (en) | 2000-01-13 | 2003-02-04 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
US6790989B2 (en) | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
WO2001087328A2 (en) * | 2000-05-12 | 2001-11-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
CA2412730C (en) * | 2000-06-15 | 2011-08-16 | Smithkline Beecham Corporation | Method for preparing a physiologically active il-18 polypeptide |
DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
ZA200304059B (en) * | 2000-12-28 | 2004-07-06 | Daiichi Seiyaku Co | VLA-4 inhibitors. |
CA2430978C (en) * | 2000-12-28 | 2012-05-15 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
UA80676C2 (en) * | 2001-01-29 | 2007-10-25 | Applied Research Systems | Use of il-18 inhibitors for the treatment and/or prevention of cardiomyopathy |
WO2002085899A1 (en) | 2001-04-19 | 2002-10-31 | Vertex Pharmaceuticals Incorporated | Heterocyclyldicarbamides as caspase inhibitors |
DE60216807T2 (de) * | 2001-10-04 | 2007-10-04 | Ortho-Mcneil Pharmaceutical, Inc. | Triazepin-derivate als neurotrope mittel |
US6821993B1 (en) | 2001-10-04 | 2004-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Triazepine derivatives as neurotrophic agents |
AU2003238948A1 (en) * | 2002-06-05 | 2003-12-22 | Sunesis Pharmaceuticals, Inc. | Caspase-1 inhibitors and methods for their use |
WO2004002961A1 (en) | 2002-06-28 | 2004-01-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
WO2004047864A1 (en) * | 2002-11-26 | 2004-06-10 | Advanced Biotherapy, Inc. | Treatment of skin diseases |
TW200500343A (en) | 2002-12-20 | 2005-01-01 | Vertex Pharma | Caspase inhibitors and uses thereof |
PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
AU2004275821A1 (en) * | 2003-09-25 | 2005-04-07 | Dmi Biosciences Inc. | Methods and products which utilize N-acyl-L-aspartic acid |
CA2547670A1 (en) * | 2003-12-01 | 2005-06-16 | Vertex Pharmaceuticals Incorporated | Treating infectious diseases using ice inhibitors |
CN100441186C (zh) * | 2003-12-03 | 2008-12-10 | 和记黄埔医药企业有限公司 | 伪石蒜碱的医药用途 |
ES2523147T3 (es) * | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
EP2270004A1 (en) * | 2004-02-27 | 2011-01-05 | Vertex Pharmceuticals Incorporated | Caspase inhibitors and uses thereof |
JP4898658B2 (ja) | 2004-03-12 | 2012-03-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体 |
JP2007534688A (ja) * | 2004-04-22 | 2007-11-29 | ザ プロクター アンド ギャンブル カンパニー | サイトカイン阻害物質としての三置換尿素類 |
CA2566362C (en) | 2004-05-15 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Treating seizures using ice inhibitors |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CN1980658A (zh) | 2004-05-27 | 2007-06-13 | 沃泰克斯药物股份有限公司 | 治疗自身炎性疾病的ice抑制剂 |
GB0515323D0 (en) * | 2005-07-26 | 2005-08-31 | Electrophoretics Ltd | Mass labels |
DE102005048293A1 (de) * | 2005-10-08 | 2007-04-12 | Sanofi-Aventis Deutschland Gmbh | Retardformulierung für Pralnacasan |
EP1826199A1 (en) * | 2006-02-27 | 2007-08-29 | Technische Universität Wien | Modified amino acids |
US20100099845A1 (en) * | 2006-09-15 | 2010-04-22 | University Of Utah Research Foundation | Protected enantiopure trifluorothreonines and methods of making and using same |
CN101772577A (zh) | 2007-08-03 | 2010-07-07 | 塞诺菲-安万特股份有限公司 | 半胱天冬蛋白酶成像探针 |
CN102065893A (zh) * | 2008-04-15 | 2011-05-18 | 萨可德公司 | Lfa-1拮抗剂向胃肠系统的递送 |
US9365612B2 (en) | 2010-01-29 | 2016-06-14 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Caspase inhibitors |
WO2012061786A1 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
EP2848696A1 (en) | 2013-09-13 | 2015-03-18 | Sanofi-Aventis Deutschland GmbH | Caspase-1 imaging probes |
WO2015069593A1 (en) * | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Substituted pyridine derivatives useful as gsk-3 inhibitors |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
US10640495B2 (en) | 2015-07-07 | 2020-05-05 | Shionogi & Co., Ltd. | Heterocycle derivatives having TrkA inhibitory activity |
WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
ES2912295T3 (es) | 2016-12-09 | 2022-05-25 | Denali Therapeutics Inc | Compuestos útiles como inhibidores de RIPK1 |
EP4165037A4 (en) | 2020-06-10 | 2024-07-03 | Aligos Therapeutics Inc | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF CORONAVIRUS, PICORNAVIRUS AND NOROVIRUS INFECTIONS |
CA3198024A1 (en) * | 2020-11-13 | 2022-05-19 | Sampath Kumar Anandan | Dichlorophenol hsd17b13 inhibitors and uses thereof |
IL309732A (en) | 2021-07-09 | 2024-02-01 | Aligos Therapeutics Inc | Antiviral compounds |
TW202334164A (zh) | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US5985863A (en) * | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US4276298A (en) | 1978-03-24 | 1981-06-30 | Merck & Co., Inc. | 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors |
US4337346A (en) * | 1978-11-02 | 1982-06-29 | Sumitomo Chemical Company, Limited | α-Hydroxyaldehyde and a process for preparing the same |
US4369183A (en) | 1979-09-06 | 1983-01-18 | Merck & Co., Inc. | 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors |
US4499295A (en) | 1983-05-09 | 1985-02-12 | G. D. Searle & Co. | Protease inhibitors |
US4584397A (en) | 1983-05-09 | 1986-04-22 | G. D. Searle & Co. | Protease inhibitors |
IL72523A (en) * | 1983-08-12 | 1988-06-30 | Takeda Chemical Industries Ltd | 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them |
US4551279A (en) | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
US5055451A (en) | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
US5158936A (en) | 1986-12-22 | 1992-10-27 | Syntex (U.S.A.) Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
NZ223148A (en) | 1987-01-16 | 1989-10-27 | Merrell Dow Pharma | Peptide derivatives having peptidase inhibition activity |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
US5081228A (en) | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5008245A (en) | 1988-10-27 | 1991-04-16 | University Of Kentucky Research Foundation | Novel peptidyl carbamate inhibitors of the enzyme elastase |
DK0471756T3 (da) | 1989-05-04 | 1998-05-18 | Sanofi Sa | Saccharinderivater, der er egnede som proteolytiske enzyminhibitorer, og fremstilling deraf |
ZA905737B (en) | 1989-07-26 | 1991-05-29 | Merrell Dow Pharma | Novel peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
WO1991005577A1 (en) | 1989-10-05 | 1991-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Catheter device with insertion stop means |
AU7775991A (en) | 1990-04-04 | 1991-10-30 | Immunex Corporation | Interleukin 1beta protease |
US5416013A (en) | 1990-04-04 | 1995-05-16 | Sterling Winthrop Inc. | Interleukin 1β protease and interleukin 1β protease inhibitors |
WO1991018903A1 (en) | 1990-05-25 | 1991-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Pyrrolopyridazine compounds |
US5199980A (en) | 1990-09-21 | 1993-04-06 | Multicolor Specialties, Inc. | Polyurethane-based water-in-water multicolor paint and method for making |
IL99527A (en) | 1990-09-28 | 1997-08-14 | Lilly Co Eli | Tripeptide antithrombotic agents |
EP0504938A3 (en) | 1991-03-22 | 1993-04-14 | Suntory Limited | Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient |
EP0519748B1 (en) | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
EP0533350B1 (en) | 1991-08-16 | 1999-05-26 | Merck & Co. Inc. | DNA encoding precursor interleukin 1B converting enzyme |
US5278061A (en) | 1991-08-16 | 1994-01-11 | Merck & Co., Inc. | Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme |
EP0533226A3 (en) | 1991-08-16 | 1993-08-18 | Merck & Co. Inc. | Novel chromophore containing compounds |
US6348570B1 (en) | 1991-08-16 | 2002-02-19 | Merck & Co., Inc. | Chromophore containing compounds and their use in determining interleukin-1β convertase activity |
HU220098B (hu) | 1991-08-30 | 2001-10-28 | Vertex Pharmaceuticals Incorporated | Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok |
GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
WO1993014777A1 (en) | 1992-01-31 | 1993-08-05 | Merck & Co., Inc. | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
DE69320176T2 (de) | 1992-02-21 | 1999-04-08 | Merck & Co Inc | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
WO1993025694A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Inhibitors of ced-3 and related proteins |
WO1993025683A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | A gene which prevents programmed cell death |
WO1993025685A1 (en) | 1992-06-12 | 1993-12-23 | Massachusetts Institute Of Technology | Cloning and characterization of the cell death genes ced-3 and ced-4 |
JPH08500242A (ja) | 1992-06-24 | 1996-01-16 | メルク エンド カンパニー インコーポレーテッド | インターロイキン1β前駆体の転換酵素をコードするDNA |
JP2602181B2 (ja) | 1992-07-31 | 1997-04-23 | ファイザー・インク. | 消炎薬としてのペプチジル4−アミノ−2,2−ジフルオロ−3−オクソ−1,6−ヘキサン二酸誘導体 |
US5374623A (en) | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
CA2109646C (en) | 1992-11-24 | 2000-03-07 | Gaston O. Daumy | Para-nitroanilide peptides |
EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
TW494094B (en) | 1993-04-29 | 2002-07-11 | Vertex Pharma | Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same |
US5462939A (en) | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
US5411985A (en) | 1993-05-17 | 1995-05-02 | Merck & Co., Inc. | Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme |
JPH0789951A (ja) | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
DE69413167T2 (de) | 1993-06-04 | 1999-05-06 | Vertex Pharma | Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen |
DE69408598T2 (de) | 1993-06-08 | 1998-09-17 | Vertex Pharmaceuticals Inc Cam | Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren |
EP0711174A4 (en) | 1993-06-24 | 1997-11-12 | Gen Hospital Corp | REGULATORY GENES OF PROGRAMMED CELL DEATH AND PROTEINS |
WO1995005192A1 (en) | 1993-08-13 | 1995-02-23 | Merck & Co., Inc. | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
US5486623A (en) | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
US5508262A (en) | 1993-12-15 | 1996-04-16 | University Of South Florida | Interleukin-1 receptor antagonist decreases severity of acute pancreatitis |
HU224731B1 (en) | 1994-03-31 | 2006-01-30 | Vertex Pharma | Pyrimidinyl derivatives as interleukin inhibitors and pharmaceutical compositions containing them |
AU705321B2 (en) | 1994-04-29 | 1999-05-20 | Vertex Pharmaceuticals Incorporated | Halomethyl amides as IL-1beta protease inhibitors |
CH688319A5 (fr) | 1994-06-03 | 1997-07-31 | Marcham Trading & Investment L | Procédé pour la préparation du céfixime trihydraté. |
US5552400A (en) | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5565430A (en) | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
JP2882756B2 (ja) | 1994-10-12 | 1999-04-12 | 昭和高分子株式会社 | 脂肪族ポリエステル組成物からなる延伸中空成形体 |
US5498616A (en) | 1994-11-04 | 1996-03-12 | Cephalon, Inc. | Cysteine protease and serine protease inhibitors |
TW394764B (en) | 1995-02-14 | 2000-06-21 | Mitsubishi Chemcal Corp | Oxygen-containing heterocyclic derivatives |
US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
-
1996
- 1996-12-06 US US08/761,483 patent/US6204261B1/en not_active Expired - Lifetime
- 1996-12-18 IN IN2188CA1996 patent/IN182290B/en unknown
- 1996-12-20 AU AU15222/97A patent/AU735075B2/en not_active Ceased
- 1996-12-20 TR TR2002/01216T patent/TR200201216T2/xx unknown
- 1996-12-20 CZ CZ20030411A patent/CZ300171B6/cs not_active IP Right Cessation
- 1996-12-20 IL IL12485096A patent/IL124850A0/xx unknown
- 1996-12-20 EP EP10010860A patent/EP2295442A3/en not_active Withdrawn
- 1996-12-20 NZ NZ326610A patent/NZ326610A/xx not_active IP Right Cessation
- 1996-12-20 CN CN96199828A patent/CN1229412A/zh active Pending
- 1996-12-20 CA CA002239904A patent/CA2239904C/en not_active Expired - Fee Related
- 1996-12-20 AP AP2002002540A patent/AP2002002540A0/xx unknown
- 1996-12-20 SK SK842-98A patent/SK287195B6/sk not_active IP Right Cessation
- 1996-12-20 PL PL96328527A patent/PL190736B1/pl not_active IP Right Cessation
- 1996-12-20 KR KR1020047011964A patent/KR100561504B1/ko not_active IP Right Cessation
- 1996-12-20 TR TR2002/01217T patent/TR200201217T2/xx unknown
- 1996-12-20 GE GEAP19964412A patent/GEP20022638B/en unknown
- 1996-12-20 AP APAP/P/2002/002538A patent/AP0202538A0/en unknown
- 1996-12-20 BR BRPI9612258-7A patent/BR9612258B1/pt not_active IP Right Cessation
- 1996-12-20 EP EP09004786A patent/EP2083014A3/en not_active Withdrawn
- 1996-12-20 AP APAP/P/2002/002539A patent/AP0202539A0/en unknown
- 1996-12-20 UA UA98073924A patent/UA66337C2/uk unknown
- 1996-12-20 JP JP52309897A patent/JP4205762B2/ja not_active Expired - Fee Related
- 1996-12-20 TR TR2002/01218T patent/TR200201218T2/xx unknown
- 1996-12-20 AP APAP/P/2002/002540A patent/AP0202540A0/en unknown
- 1996-12-20 CZ CZ0190698A patent/CZ298171B6/cs not_active IP Right Cessation
- 1996-12-20 WO PCT/US1996/020843 patent/WO1997022619A2/en active Search and Examination
- 1996-12-20 BR BRPI9612258A patent/BRPI9612258B8/pt unknown
- 1996-12-20 EP EP96945318A patent/EP0869967A2/en not_active Withdrawn
- 1996-12-20 NZ NZ518094A patent/NZ518094A/en not_active IP Right Cessation
-
1998
- 1998-06-05 NO NO19982597A patent/NO326882B1/no not_active IP Right Cessation
- 1998-06-11 IL IL124850A patent/IL124850A/en not_active IP Right Cessation
- 1998-06-12 IS IS4771A patent/IS4771A/is unknown
- 1998-06-19 MX MX9805016A patent/MX9805016A/es unknown
- 1998-07-13 BG BG108927A patent/BG108927A/en unknown
- 1998-07-13 BG BG102624A patent/BG64465B1/bg unknown
-
1999
- 1999-09-21 US US09/400,639 patent/US6258948B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 US US09/773,477 patent/US6423840B1/en not_active Expired - Fee Related
-
2002
- 2002-01-28 US US10/058,522 patent/US20030225269A1/en not_active Abandoned
- 2002-10-21 JP JP2002306094A patent/JP2003137896A/ja not_active Withdrawn
-
2004
- 2004-11-29 US US10/999,865 patent/US20050143436A1/en not_active Abandoned
-
2006
- 2006-09-01 HK HK06109752.3A patent/HK1089435A1/xx not_active IP Right Cessation
-
2007
- 2007-01-18 US US11/655,938 patent/US7790713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-18 JP JP2008159803A patent/JP2008285493A/ja not_active Withdrawn
-
2010
- 2010-05-24 US US12/786,221 patent/US8119631B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL124850A0 (en) | Inhibitors of interleukin-1beta converting enzyme and processes for their production | |
HUP9902254A3 (en) | Inhibitors of interleukin-1beta converting enzyme | |
HUT76622A (en) | Inhibitors of interlaukin-1beta converting enzyme | |
AU4763196A (en) | Inhibitors of microsomal triglyceride transfer protein and method | |
EP0812910A4 (en) | NEW LIPASEGEN AND METHOD FOR PRODUCING LIPASE BY USE THEREOF | |
HUP9900422A3 (en) | Novel protein and methods for the production of the same | |
EP0864654A4 (en) | STRESS-TOLERANT MICROORGANISMS AND METHOD FOR THE PRODUCTION OF A FERMENTATION PRODUCT | |
HUP9901292A3 (en) | Process for propagation and/or selection of plant material | |
AU6008996A (en) | Methods of treating plant materials with hydrolytic enzymes | |
ZA9610798B (en) | Inhibitors of interleuken-1beta converting enzyme | |
AU9733698A (en) | Process for making and uses of cordyceps fermentation products | |
EP0840784A4 (en) | METHOD FOR PRODUCING AND PURIFYING ENZYMES | |
ZA968896B (en) | Method of mobilizing hematopoietic stem cells | |
GB9524267D0 (en) | Enzyme inhibitor and method | |
GB9615852D0 (en) | Production of amino acids and enzymes used therefor | |
ZA964107B (en) | Enzyme degrading rhamnogalacturonane ii methods for obtaining said enzyme and rhamnogalacturonane ii and use of said enzyme | |
HUP9902707A3 (en) | Inhibitors of interleukin-1beta converting enzyme | |
NZ334608A (en) | Novel processes for preparing intermediates of inhibitors of enkephalinase and angiotensing converting enzymes and intermediates thereof | |
AUPN527895A0 (en) | Product and process relating to albicidin detoxification enzyme | |
AP2002002539A0 (en) | Inhibitors of interleukin-1b converting enzyme | |
GB9618888D0 (en) | Method of production and products produced thereby | |
PL310184A1 (en) | Method of obtaining carbon of plant origin | |
AUPN523795A0 (en) | Piping and method of manufacture thereof | |
GB9504419D0 (en) | Articles and method of their manufacture | |
AUPN143495A0 (en) | Enzyme inhibitors and modified enzyme |